BACKGROUND: Glucocorticoids can lead to weight gain during cancer treatment, but to the authors' knowledge, little is known regarding their long-term effects in childhood cancer survivors (CCS). METHODS: As part of the Swiss Childhood Cancer Survivor Study, the authors sent a questionnaire to CCS aged <21 years at diagnosis who were residing in Switzerland, had survived 5 years, and were aged 15 to 45 years at the time of the survey. Cumulative doses of glucocorticoids were assessed from medical records and study protocols and body mass index was calculated from self-reported height and weight at the time of the survey. The authors compared the prevalence of overweight between CCS, their siblings, and the general population (Swiss Health Survey [SHS]) and investigated the association between overweight and treatment-related risk factors using multivariable logistic regression. RESULTS: The study included 1936 CCS, 546 siblings, and 9591 SHS participants. The median age of the CCS at the time of the survey was 24 years (interquartile range, 20-31 years) and the median time since diagnosis was 17 years (interquartile range, 12-22 years). At the time of the survey, approximately 26% of CCS were overweight, a percentage that was comparable to that among siblings (24%) and the SHS participants (25%). The prevalence of overweight was 24% in CCS treated with glucocorticoids only (686 CCS), 37% in those treated with cranial radiotherapy (CRT) (127 CCS), and 49% in those who received treatment with both glucocorticoids and CRT (101 CCS) (P <.001). The authors found no evidence of a dose-response relationship between cumulative glucocorticoid doses and overweight and no evidence that CRT modified the effect of the cumulative glucocorticoid dose on overweight. CONCLUSIONS: The results of the current study suggest that glucocorticoids used for the treatment of childhood cancer are not associated with longterm risk of overweight. Cancer
INTRODUCTION
The glucocorticoids prednisone and dexamethasone currently are part of the standard treatment of patients with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). The type of glucocorticoid, dose, and duration of treatment can differ by cancer treatment protocol. 1 Cancer treatment with glucocorticoids can lead to weight gain originating in physiological (eg, altered cortisol concentrations and adipose tissue metabolism) and psychological changes that among others may influence appetite and lower energy expenditure due to physical inactivity. 1, 2 An excess of dietary intake and physical inactivity during treatment could be the basis for behavioral changes in the long-term leading to continuous weight gain during survivorship. Prednisone and dexamethasone have similar mechanisms of action, but dexamethasone in the dose range commonly used causes more adverse effects such as acute metabolic side effects, infections, osteopenia, and behavioral abnormalities. 1, 3 Other treatments for childhood cancer also can affect the development of overweight and obesity, in particular cranial radiotherapy (CRT). CRT impairs the hypothalamic-pituitary axis, which in turn can lead to growth hormone deficiency and leptin insensitivity. 4 To the best of our knowledge, treatment protocols for ALL have not routinely prescribed CRT since the 1980s, and the overall cumulative CRT doses have decreased. 5 In contrast, cumulative glucocorticoid doses have increased in the United States, and prednisone has been replaced in part with the more potent dexamethasone. 6, 7 Many childhood cancer survivors (CCS) are reported to be overweight, especially in the United States, despite decreased doses of CRT. 8 Therefore, glucocorticoids might be implicated in excessive weight gain during cancer treatment. 3, 7 However, to the best of our knowledge, the question of whether glucocorticoids have a longer-lasting effect on weight is uncertain, and any such effect may depend on the dose and duration of treatment. Research has yielded contradictory results. One small study of survivors of ALL (169 survivors) reported a 6-fold increased risk of being overweight or obese among those who were treated with the highest cumulative doses of glucocorticoids (10,000 mg/m 2 ) compared with those receiving the lowest doses (<7500 mg/m 2 ) 5 years after diagnosis, 9 whereas another US study found no dose response effects 10 years after diagnosis. 10 In a US study, treatment with glucocorticoids was found to be associated with obesity 25 years after diagnosis among 776 CCS who were treated with CRT, but to our knowledge the cumulative dose and type of glucocorticoid used were not assessed. 11 To the best of our knowledge, previous studies to date have focused mainly on the acute effects of glucocorticoids during or shortly after treatment, 9, [12] [13] [14] [15] [16] have not assessed cumulative glucocorticoid dose, 11, 13 and often have relatively low numbers of participants (<200 individuals). 9, [12] [13] [14] [15] [16] [17] [18] Thus, to our knowledge, it remains unclear whether glucocorticoids affect overweight in CCS long after treatment.
In the current study, we analyzed data from the Swiss Childhood Cancer Survivor Study (SCCSS) to investigate whether: 1) overweight in long-term CCS (average of 17 years after diagnosis) is associated with the cumulative glucocorticoid dose received; 2) there is a dose-response relationship between cumulative glucocorticoid dose and body mass index (BMI); and 3) the respective effects of prednisone and dexamethasone differ. We studied the entire group of CCS and examined the 3 cancer types treated most frequently with glucocorticoids (ALL, NHL, and HL) separately.
MATERIALS AND METHODS

Sampling
The Swiss Childhood Cancer Survivor Study
The SCCSS is a long-term follow-up study of patients registered in the Swiss Childhood Cancer Registry (SCCR; www.childhoodcancerregistry.ch) who were diagnosed beginning in 1976 and survived 5 years after their cancer diagnosis. 19 The SCCR is a population-based registry that includes all children and adolescents aged <21 years in Switzerland who are diagnosed with leukemia, lymphoma, central nervous system tumors, malignant solid tumors, or Langerhans cell histiocytosis. 20, 21 Ethical approval of the SCCR and the SCCSS has been given by the Ethics Committee of the Canton of Bern (KEK-BE 166/2014).
As part of the SCCSS, we traced the addresses of all CCS diagnosed between 1976 and 2005, to whom we sent questionnaires between 2007 and 2013. A second questionnaire was sent to nonresponders 4 to 6 weeks later. If these individuals again did not respond, we contacted them by telephone. Our questionnaire included core questions from the US and UK CCS studies, 22, 23 with added questions regarding health behaviors and sociodemographic measures from the Swiss Health Survey (SHS) 24 and the Swiss Census. 25 Detailed information regarding the study design has been published previously.
19,26
Comparison groups
We used 2 comparison groups in this study: 1) siblings of the CCS and 2) a random sample of the general Swiss population represented by data from the SHS. The sibling survey was conducted from 2009 through 2012. We asked CCS for consent to contact siblings and for contact information. We sent siblings the same questionnaire as the CCS, omitting questions regarding cancer history. Siblings who did not respond received another copy of the questionnaire 4 to 6 weeks later, but were not contacted by telephone. 19 The second comparison group consisted of participants in the 2012 SHS questionnaire. 24 This is a nationally representative telephone survey that is repeated every 5 years. The SHS compiled a randomly selected sample of Swiss households with telephone landlines and attempted to contact someone in each household. Sampling was stratified by region and in the selected households the survey was administered to the consenting household member aged 15 years who first answered the phone.
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Measurements
Body weight and BMI
Body weight and height at the time of the survey were collected from the questionnaires. We instructed all study participants and control groups to record height without shoes and weight without clothes. We calculated BMI by dividing weight by height in meters squared (kg/m 2 ). An adult BMI < 18.5 kg/m 2 was classified as underweight, a BMI 18.5 to < 25 kg/m 2 was classified as normal weight, and a BMI 25 kg/m 2 was classified as overweight including obesity. 27 For adolescents aged 15 to 19 years at the time of the survey, we standardized BMI into z scores for age and sex using the latest available Swiss references.
28 BMI z scores < -2 were classified as underweight, those from -2 to 1 as normal weight, and those >1 as overweight including obesity. 29 
Glucocorticoids
We calculated prednisone and/or dexamethasone doses based on the intended doses in the cancer treatment protocol and, if applicable, the treatment arm. Glucocorticoid tapering was taken into account if protocols indicated this. In the event that tapering information regarding duration and dose was missing, we assumed that the dose decreased by 50% of the prior dose in 3 steps over 3 days. The few protocols (3%) that prescribed glucocorticoids by body weight (in mg/kg) were converted into dose per body surface area (mg/m 2 ) by multiplying the dose in mg/kg by a conversion factor of 30, which represents an average of the factors for individuals weighing 20 and 60 kg. 30 Glucocorticoids administered by the intrathecal route and those used for supportive care or immunosuppression were not taken into consideration. 1 Treatment protocols that were included came from the Swiss Pediatric Oncology Group (31%), the Pediatric Oncology Group (29%), the Berlin-Frankfurt-Muenster Study Group (24%), the German Society of Pediatric Oncology and Hematology (7%), and others (9%) (see Supporting Table 1 ). In 67 cases in which the study arm was unknown, survivors were assigned to the protocol arm with the lowest glucocorticoid dose. We calculated the total cumulative glucocorticoid dose in an equivalent of prednisone for each patient using the following formula: cumulative glucocorticoid dose 5 cumulative prednisone dose 1 (cumulative dexamethasone dose 3 6.67) in mg/m 2 . 31 The recommended cumulative glucocorticoid doses decreased over time when all cancer types were combined, and specifically for each type of cancer, with the exception of ALL protocols, for which doses increased (see Supporting Fig. 1 ). We assessed other clinical and sociodemographic variables as described previously. 26 
Statistical Analysis
In the current study, we included all SCCSS survivors and their siblings and the SHS participants in the general population who were aged 15 to 45 years at the time of the survey and provided self-reported height and weight (see Supporting Fig. 2 ). We excluded CCS who had undergone hematopoietic stem cell transplantation; this specific group is at substantial risk of underweight due to chronic graft-versus-host disease and long-term immunosuppression with recurrent infections. 32 For a better comparison between CCS and their peers, we standardized comparison groups for sex, age at the time of the survey, migration background, and language region as described previously. 26 First, we assessed whether overweight at the time of the survey was associated with the cumulative glucocorticoid dose received during treatment. We determined these associations using multivariable logistic regression within all CCS, and within patients with the 3 cancer types frequently treated with glucocorticoids. We divided BMI into 2 categories, overweight (overweight and obesity) versus non-overweight (underweight and normal), because the group of obese individuals was small and the glucocorticoids and CRT risk estimates for the 2 categories of overweight and obesity had the same direction and comparable magnitude. Cumulative prednisone and glucocorticoid use was divided into 3 categories: 1) lower than the median intake of all CCS; 2) median to third quartile, and 3) equal to or higher than the third quartile. Cumulative dexamethasone was divided into 2 categories: lower than the median intake of all CCS, and equal to or higher than the median. We adjusted the models for sex, age at diagnosis, time since diagnosis, and cumulative CRT and/or glucocorticoid dose. We used interaction terms to test whether age, sex, and the clinical variables (eg, age at diagnosis, year of diagnosis, time since diagnosis, and CRT) modified the effect of cumulative glucocorticoid dose on overweight because these variables are related to the total dose. Second, we illustrated the doseresponse relationship by comparing the distribution of BMI by cumulative glucocorticoid dose in steps of 1000 mg/m 2 (prednisone and total glucocorticoids) or 100 mg/m 2 (dexamethasone) with box plots. Because approximately 26% of CCS were aged 15 to 19 years at the time of the survey, we used BMI z scores for all CCS. We used trend tests to test for an ordered relationship between cumulative glucocorticoid dose categories and BMI z scores. Third, we examined whether effects differed
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Cancer September 1, 2018 between dexamethasone and prednisone treatment, again using multivariable logistic regression models. Finally, we performed sensitivity analyses to compare standardized data for sex, age, migration background, and language region with nonstandardized data in all comparison groups according to the distribution in CCS. For the 67 survivors for whom the study arm was unknown, we performed sensitivity analyses in which they were excluded or were assigned to the protocol arm with the highest glucocorticoid dose instead of the lowest. We used Stata statistical software (version 14; StataCorp LLC, College Station, Texas) for all statistical analyses.
The current study has a ClincialTrials.gov identifier (NCT03297034).
RESULTS
Response Rate and Characteristics of the Study Populations
Among 4116 eligible CCS, we traced and contacted 3593 individuals, 2527 of whom returned the SCCSS questionnaire. We excluded 119 participants who did not report height and weight, 355 who were aged < 15 years or > 45 years, and an additional 117 participants who had received hematopoietic stem cell transplantation. We thus included 1936 CCS in the current study, 546 of whom had been treated for ALL, 114 of whom had been treated for NHL, 195 of whom had been treated for HL, and 1081 of whom had been treated for other types of cancer (see Supporting Fig. 2) .
We received consent to contact 1530 siblings, 866 of whom returned the questionnaire. A total of 300 siblings were outside the age range and 20 did not report height and weight; thus, 546 siblings finally were included in the analyses. Of the 41,008 households surveyed in the general population (SHS), 21,597 replied to the survey. In those responding households, 9591 individuals aged 15 to 45 years were included in the analysis.
Among CCS, the median age at the time of diagnosis was 8 years (interquartile range [IQR], 4-13 years) for the population overall, 5 years (IQR, 3-9 years) for received a classification protocol, after which no protocol information was given in their medical record; and 9 (50%) survivors were diagnosed before 1990.
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Overweight and Glucocorticoid Therapy
The prevalence of overweight among all CCS was 26% at the time of the survey. This was similar to the overweight prevalence in the comparison groups after standardization according to CCS: 24% in siblings (P 5 .34) and 25% in the general population (P 5 .48) ( Table 2) (See Supporting Fig. 3 ). When we stratified CCS by treatment, we found that the prevalence of overweight was 23% in CCS treated with no glucocorticoids and no CRT (205 of 889 CCS), 24% in those treated with glucocorticoids alone (166 of 686 CCS), 37% in CCS treated with 20 grays (Gy) of CRT (47 of 127 CCS; P < .01), and 49% in those treated with both glucocorticoids and 20 Gy of CRT (49 of 101 CCS; P < .001) (Fig. 1 ). There was a weak trend (P 5 .08) suggesting that the effect of CRT tended to be higher in CCS who also were treated with glucocorticoids. In multivariable logistic regression models, we found that overweight was not associated with cumulative glucocorticoid dose either in CCS overall or in the survivors of the 3 cancer types treated frequently with glucocorticoids (Table 3) . However, CCS and survivors of ALL who were treated with 20 Gy of CRT were found to be more likely to be overweight. Interaction tests did not suggest that the cumulative effect of glucocorticoids differed by sex, age, year of diagnosis, time since diagnosis, chemotherapy, CRT, or history of disease recurrence (see Supporting Table 2 ). 
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Dose-Response Relationship Between Overweight and Glucocorticoids
We found no evidence supporting a dose-response relationship between cumulative prednisone, dexamethasone, or both combined and BMI z scores, either when stratifying for CRT (P for trend for no CRT 5 .994; P for trend for < 20 Gy of CRT 5 .510, and P for trend for 20 Gy of CRT 5 .174) (Fig. 2) , or when analyzing the entire CCS group adjusted for cumulative CRT dose (P for trend for prednisone 5.085, P for trend for dexamethasone 5.176, and P for trend for glucocorticoids 5.583) (see Supporting Fig. 4) . CCS who received treatment with high prednisone doses (8000 mg/m 2 ) tended to have higher BMI z scores. In survivors of ALL, we also observed no dose-response relationship (P for trend for prednisone 5 .223, P for trend for dexamethasone 5.063, and P for trend for glucocorticoids 5.512) (see Supporting Fig. 5 ).
Prednisone Versus Dexamethasone
In unadjusted analyses, CCS who were treated with the highest cumulative dose of prednisone (5824 mg/m 2 ) tended to be more overweight than those treated with the lowest dose (<2520 mg/m 2 ). This was not found to be statistically significant after adjustment for time since diagnosis. We made further adjustments for sex, age at diagnosis, cumulative CRT, and dexamethasone (Table  3) . In contrast, survivors of ALL who were treated with a higher dose of dexamethasone (1260 mg/m 2 ) were found to be less likely to be overweight compared with those treated with a lower dose (<1260 mg/m 2 ).
DISCUSSION
At a median of 17 years after their cancer diagnosis, 26% of CCS in Switzerland were overweight. This prevalence is comparable to that in siblings and healthy peers in the general population. The prevalence of overweight was 23% in those CCS treated with glucocorticoids, but was higher for CCS treated with CRT doses 20 Gy (37%), and were yet higher among CCS treated with both glucocorticoids and CRT doses 20 Gy (49%). The effect of CRT on overweight tended to be higher if CCS also were treated with glucocorticoids, but the power for interaction tests was low. There was no evidence of a dose-response relationship between the cumulative glucocorticoid dose and being overweight, except for a possible effect at the highest doses (prednisone 8000 mg/m 2 ). Overweight and obesity during treatment is frequent in patients with ALL who receive high doses of glucocorticoids, 33 but to the best of our knowledge the long-term Global P value was calculated from the likelihood ratio test.
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Cancer September 1, 2018 impact of glucocorticoid therapy on overweight has not been well studied to date. A US study of 784 survivors of ALL followed for >26 years found an association between obesity and CRT, but not cumulative glucocorticoid dose. This finding is similar to that of the current study, but survivors of ALL treated with low glucocorticoid doses in the US study received high CRT doses. This could have masked an association between glucocorticoids and obesity. 34 A Dutch study of 113 survivors of ALL 10 years after treatment found that higher cumulative prednisone doses led to higher BMI z scores at the end of treatment and shortly thereafter, but not in the long term. 18 The cumulative prednisone doses in the study were much higher than those in the current study; of the 65 survivors who received only prednisone, 60 (92%) had received a cumulative dose of 9800 mg/m 2 . We also found post hoc evidence that higher cumulative prednisone doses (8000 mg/m 2 ) lead to more overweight, but after multivariable adjustment this effect disappeared. A doseresponse association between cumulative glucocorticoid dose and BMI also was observed in a longitudinal singlecenter study of 165 survivors of ALL in the United States. BMI was assessed 5 years after diagnosis and again, cumulative glucocorticoid doses were higher (approximately 50% of survivors had a cumulative dose of >9000 mg/ m 2 ). 9 We found on univariable analyses that survivors who received the highest cumulative prednisone dose (5824 mg/m 2 ) were more likely to be overweight. After adjustment, the association was found to be similar in magnitude and direction, but was no longer statistically significant. We did not find an association between cumulative dexamethasone dose and overweight in CCS. However, the follow-up was longer in CCS who were treated with prednisone because dexamethasone was introduced more recently. Survivors of ALL who received a cumulative dexamethasone dose of 1260 mg/m 2 were even less likely to be overweight than those who were treated with a lower dose. The dose-response relationship between cumulative dexamethasone and BMI z scores demonstrated an effect with higher doses of dexamethasone. Given the wide confidence intervals, this finding most likely is due to chance. The effect also could be a surrogate for more severe disease and more intense treatment, leading to less weight gain over time. To the best of our knowledge, studies examining the association between glucocorticoids and overweight in survivors of tumors other than ALL are limited. In 88 survivors of HL who had been in complete continuous remission for 16 years, no difference in BMI was found between those treated with and without prednisone. 17 The glucocorticoid dose is lower and the duration of chemotherapy is shorter in survivors of HL compared with survivors of ALL. We noted no association between glucocorticoids and overweight in either survivor group.
To the best of our knowledge, the current study is the largest of its kind to examine cumulative glucocorticoid dose and overweight in CCS long after the end of treatment. It also had a specific focus on survivors of ALL, NHL, and HL, who usually receive high doses of glucocorticoids. Other strengths include its national coverage and high response rate, which increase confidence that the results are representative, as does its access to both socioeconomic factors and detailed treatment data. We also compared CCS with 2 other groups from whom contemporaneous data were collected: CCS siblings and the general population in Switzerland. Among the study's limitations was the unavailability of patient dose levels, which necessitated deriving cumulative glucocorticoid doses from cancer protocol information. This could have led to either underestimation or overestimation of the cumulative glucocorticoid dose when the protocol arm was unknown, but the study arm was unknown for only 67 survivors. Sensitivity analyses in which survivors with unknown study arms were excluded or were assigned to the highest dose instead of the lowest dose reported the same results. Only 239 CCS were treated with dexamethasone because, although we included CCS diagnosed since 1976, dexamethasone use has increased only recently. 7 Height and weight at the time of the survey were self-reported, and therefore both underreporting and Cancer September 1, 2018 Overweight in Childhood Cancer Survivors/Belle et al overreporting could have occurred. However, because height and weight were self-reported in all study populations, we expected the degree of nondifferential errors of BMI assessment to be similar across all CCS, the comparison groups, and across CCS treated with different glucocorticoid doses. Finally, we used BMI as a measure of overweight. BMI measures neither the ratio of lean to fat mass nor fat distribution. Because glucocorticoids have a catabolic effect on muscle, CCS could have less lean mass and more fat mass than the general population with a similar BMI. 35 However, BMI is a practical and inexpensive proxy measure of overweight that is widely used in population-based studies.
The treatment of childhood cancer increases survivors' risk of chronic diseases. Overweight can worsen disease burden, in particular when it involves the development of endocrine complications such as type II diabetes. Although the results of the current study do not suggest that glucocorticoids are associated with long-term overweight, advice regarding weight control, a healthy lifestyle, and physical activity always should be part of survivorship care, with a special focus on patients who received CRT as well as potentially those who received very high doses of glucocorticoids.
However, the findings of the current study essentially are comforting: treatment with glucocorticoids leads to overweight at the time of treatment, 9, [12] [13] [14] 16 but the results herein suggest that glucocorticoid treatment is not a reason for concern for long-term overweight in CSS. 
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